Stocklytics Platform
Kala Pharmaceuticals
KALA53
$6.84arrow_drop_down1.51%-$0.10
NASDAQ - As of Mar 13, 7:44 PM EDT Market Closed
KALA53

$6.84

arrow_drop_down1.51%

Performance History

arrow_drop_down10.28%

(-$0.78 )

Stocklytics logo
Key Stats
Open$7.01
Prev. Close$6.95
EPS-11.67
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$41.11M
PE Ratio-
LOWHIGH
Day Range6.72
7.14
52 Week Range4.21
11.59
Ratios
P/B Ratio6.12
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %5.85%
EBITDA Margin %-
ROE %-430.96%
EPS-11.67

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

Correlated Companies

Eli Lilly & Co
LLY84
Price$801.65
Perf. (24h)arrow_drop_down2.45%-$20.21
Market Cap$720.01B
UnitedHealth Group
UNH69
Price$481.52
Perf. (24h)arrow_drop_up0.08%$0.40
Market Cap$444.64B
Johnson & Johnson
JNJ61
Price$162.99
Perf. (24h)arrow_drop_up0.08%$0.14
Market Cap$397.30B
AbbVie
ABBV67
Price$211.55
Perf. (24h)arrow_drop_down0.24%-$0.50
Market Cap$373.46B

About Kala Pharmaceuticals (KALA)

Kala Pharmaceuticals Inc (KALA) is a biopharmaceutical company focused on the development and commercialization of therapies for eye diseases. The company's lead product candidate is KPI-121 0.25%, which is a nanoparticle formulation of loteprednol etabonate for the treatment of inflammation and pain following ocular surgery. Kala Pharmaceuticals has completed two Phase 3 clinical trials for KPI-121 0.25% and has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the product. The company is also exploring the use of its proprietary technology platform, AMPPLIFY, to develop additional ocular therapies.
Kala Pharmaceuticals Inc's stock price history shows some volatility since its initial public offering (IPO) in 2017. The stock has experienced both ups and downs, reflecting the uncertainty and risk inherent in the biopharmaceutical industry. However, Kala Pharmaceuticals has made progress in advancing its pipeline and obtaining regulatory approvals, which has contributed to positive investor sentiment. As of the latest available data, Kala Pharmaceuticals' market capitalization stands at approximately $XXX million. The PEG ratio, which compares a company's price-to-earnings ratio to its growth rate, can provide insight into a stock's valuation. Kala Pharmaceuticals' PEG ratio is currently not available. Comparing Kala Pharmaceuticals' performance to its industry peers can help investors assess its relative strength. The company's stock performance may be influenced by both industry-wide factors and company-specific developments. Kala Pharmaceuticals' 52-week range indicates the highest and lowest prices at which the stock has traded over the past year. The day range represents the high and low prices of the stock during a particular trading session. Finally, the trading volume measures the number of shares that are bought and sold during a given period.
Show more
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Mark T. Iwicki
Headquarters
Arlington
Employees
34
Exchange
NASDAQ
add Kala Pharmaceuticals to watchlist

Keep an eye on Kala Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Kala Pharmaceuticals 's (KALA) price per share?

The current price per share for Kala Pharmaceuticals (KALA) is $6.84. The stock has seen a price change of -$0.11 recently, indicating a -1.51% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Kala Pharmaceuticals (KALA)?

For Kala Pharmaceuticals (KALA), the 52-week high is $11.6, which is 69.39% from the current price. The 52-week low is $4.21, the current price is 62.59% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Kala Pharmaceuticals (KALA) a growth stock?

Kala Pharmaceuticals (KALA) has shown an average price growth of -1.65% over the past three years. It has received a score of 12 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Kala Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Kala Pharmaceuticals (KALA) stock price performance year to date (YTD)?

As of the latest data, Kala Pharmaceuticals (KALA) has a year-to-date price change of -1.37%. Over the past month, the stock has experienced a price change of -8%. Over the last three months, the change has been 12.4%. Over the past six months, the figure is 15.04%. Looking at a longer horizon, the five-year price change stands at -98.07%.
help

Is Kala Pharmaceuticals (KALA) a profitable company?

Kala Pharmaceuticals (KALA) has a net income of -$42.2M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$39.15M. Furthermore, the EBITDA is -$40.06M.
help

What is the market capitalization of Kala Pharmaceuticals (KALA)?

Kala Pharmaceuticals (KALA) has a market capitalization of $41.12M. The average daily trading volume is 6.9, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level